- BIOETHICS FORUM ESSAY
Moratorium on Human Genome Editing: Time to Get It Right
On March 13, Nature published a call for a global moratorium on heritable human genome editing signed by several prominent CRISPR researchers and bioethicists, including Eric Lander, Françoise Baylis, and Emmanuelle Charpentier. They proposed a temporary moratorium on germline genome editing to create gene-edited children. This moratorium is not designed to stop in vitro research in the laboratory or research on somatic (nonreproductive) cells, but it would cover the implantation of gene-edited embryos or the creation of children using gene-edited sperm or eggs. The authors specifically cite safety, scientific, technical, medical, and ethical/moral/societal reasons for calling the moratorium. Importantly, it is supported by the National Institutes of Health in the United States and the European Society for Human Reproduction and Embryology (ESHRE).
Although some criticism, notably from CRISPR pioneer Jennifer Doudna (who did not sign the moratorium statement), has focused on the possibility of a moratorium “of indefinite length,” this argument is somewhat of a straw man as the proposed moratorium is temporary. Doudna has also criticized a moratorium as being something that will suppress open discussion and transparency. In our view (and likely that of the Nature authors), this is not the case. A moratorium will allow time for open discussion, broad societal consensus-building (which may not happen if germline genome editing is pushed quickly into clinical trials), and the creation of international and national governing bodies to help ensure transparency and proper regulation.
We find it curious that the WHO expert advisory committee on developing global standards for governance and oversight of human genome editing has also avoided using the word moratorium. When asked about it at a press conference, the codirector of the committee responded, “I don’t think a vague moratorium is the answer to what needs to be done.” Vague is not a word that characterizes the proposed moratorium (in fact, it’s quite specific in its requests) and it seems to perpetuate the misunderstanding that the moratorium would not have a defined length.
A particularly interesting unanswered question is why some people are resistant to using the word moratorium, even when they would admit that there is an “effective moratorium” imposed by self-regulation in science. However, pushing against moratoria is a regular occurrence regarding genome editing. For example, in 2015 Harvard psychology professor Steven Pinker, a proponent of “more gas” and “less brake” in relation to CRISPR gene editing, was quoted in an interview with Paul Knoepfler as saying that a “moratorium would only reinforce the pernicious aura of dread that surrounds genomic modifications.” He went on to discuss the death of Jesse Gelsinger and the subsequent moratorium in 2003 on gene therapy trials by the Food and Drug Administration. Pinker also said that he was “skeptical that we’ll ever see genetic enhancement of babies—the outcome that the prohibitionists and moratoristas dread and that many bioethicists blithely assume is inevitable.”
Some have considered the Chinese scientist He Jiankui’s gene editing of babies, Lulu and Nana, to be enhancement because of unknown effects of the edited gene in the brain and because the question of whether HIV resistance is an enhancement occupies a grey zone. In this regard, it only took three years to prove Pinker wrong and perhaps a bit naïve. It now seems clear that in the face of the current culture surrounding frontier science, the fast-paced progress in CRISPR gene editing may continue to outpace even the most alarmist of bioethicists.
The proposed moratorium on heritable human genome editing would be a big step in the right direction by allowing for Slow CRISPR Science. This would allow for further safety and efficacy studies to take place in the laboratory before pushing forward into clinical trials. The moratorium call is careful not to prohibit these activities, which will be vital to address concerns, especially those of safety such as off-target effects of gene-editing techniques and the long-term consequences of modifying human genes.
The ethical and societal concerns raised by this technology – such as reaching broad societal consensus – are another matter. The creation of an appropriate forum for having these discussions is a necessary step to ensure a broad conversation. The primary considerations when building a public forum for these discussions will be ensuring an accessible – for lay audiences – focus on the scientific and technical issues, as well as the societal and ethical issues while meaningfully including the public.
An article in the journal Science by the people behind Editing Nature disapprovingly notes that “most frameworks for regulatory decision-making continue to largely preference science-based knowledge and technical risk assessments.” This kind of organizing, like the Asilomar conference on recombinant DNA Technologies held in 1975, has been considered misguided by some because it leaves out policy-makers, ethicists, philosophers, and the public while focusing heavily on scientific voices.
In practice, participatory processes can be effective and helpful for ensuring that a community feels involved in decisions that directly affect them. Public participation seeks to engage the people who will be affected by a decision and involve them in the decision-making process with the goal that their input will impact the final action taken. At its heart are three key aspects: the pragmatic, the political, and the epistemic. It is pragmatic because is purported to lead to more valuable outcomes and “increase the usefulness of the knowledge that is created.” It is political because it builds public trust, accountability, and transparency for the decision-making process. Finally, it is epistemic because it ultimately produces more complete knowledge; public participation “aims to enhance the validity of the produced knowledge.” This kind of process could allow for broad public input on the issue of human germline genome editing.
Consider the work being done by by Kevin Esvelt on Nantucket and Martha’s Vineyard. Esvelt is working on a CRISPR implementation of gene drive that would modify white-footed mice to be resistant to the bacterium that causes Lyme disease. In this way, ticks would not pick up the bacterium from the mice and pass it on to humans. Importantly, Esvelt immediately contacted and started working with the local governments and communities to determine if they were interested in attempting this, and he has respected their decisions thus far. He has even helped develop a local governance framework, in the form of a steering committee, to help organize these conversations and give deciding power to the communities.
Esvelt’s process allows for enhancing public trust, as well as accountability and transparency, regarding the decision to move forward with his field testing of gene-editing technology. Esvelt’s work will lay some foundational building blocks for how we might explore achieving broad societal consensus on whether to continue with human germline genome editing and if so, how we ought to do it.
Public participation is likely the only way we can ensure that the decisions made are those that are in the public interest and for the common good, and that they represent the will of the people of any given society. Although opinions on whether to continue with germline genome editing will vary, as will the reasons for these opinions, we believe there is a moral imperative to ensure that the public, the owners of the human genome, are included in this conversation. Ultimately, a moratorium on editing in the human germline allows us time to get this right.
Landon J. Getz is a PhD candidate in microbiology and immunology at Dalhousie University in Canada, @LandonGetz. Graham Dellaire is director of research and a professor of pathology at Dalhousie University, @DocDellaire.
Read More Like This45% of The Hastings Center’s work is supported by individual donors like you. Support our work.